FUMARATE, TARTRATE, MALATE, AND CITRATE SALTS OF AN EGFR INHIBITOR

Title:

FUMARATE, TARTRATE, MALATE, AND CITRATE SALTS OF AN EGFR INHIBITOR

Document Type and Number:

WIPO Patent Application WO/2024/096624

Kind Code:

A1

Abstract:

The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-((6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide, compositions thereof, methods of preparation thereof, and methods of their uses.

More Like This:

JP5015397	Sulfonamide derivative active as a medicine
WO/2005/033096	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF
WO/2022/271749	HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER

Inventors:

PARK BYUNGWOO (KR)
LEE YOUNHO (KR)
KIM DAEKWON (KR)

Application Number:

PCT/KR2023/017405

Publication Date:

May 10, 2024

Filing Date:

November 02, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

VORONOI INC (KR)

International Classes:

C07D413/14; A61K31/506; A61P35/00; C07C57/15; C07C59/245; C07C59/255; C07C59/265

Domestic Patent References:

WO2004087700A1	2004-10-14
WO2019010295A1	2019-01-10

Foreign References:

US20220073505A1	2022-03-10
US20160102076A1	2016-04-14

Other References:

FINLAY, M. R. V. ET AL.: "Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 2014, pages 8249 - 8267, XP055193649, DOI: 10.1021/jm500973a

Attorney, Agent or Firm:

CHANG, Duck Soon et al. (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD AND APPARATUS FOR MANAGING BACKHAUL INFORMATION-BASED SESSION IN WIRELESS COMMUNICATION SYSTE...

Next Patent: SEPARATOR SUBSTRATE FOR ELECTROCHEMICAL DEVICE, AND SEPARATOR COMPRISING SAME